Abstract: Targeted therapies of breast cancer offer a possibility of effective and individualized therapy based on the molecular profile of the tumor. Currently there are three main types of targeted therapeutic drugs for breast cancer, the first category is the monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) including trastuzumab, pertuzumab, lapatinib, TDM1. The second is targeting VEGF such as bevacizumab. The last one everolimus is a mammalian target of rapamycin (mTOR) inhibitors. A number of trials suggest that the addition of targeted therapy to chemotherapy or endocrine therapy significantly improved PFS and OS in patients with breast cancer.

Key words: Breast neoplasms, Molecular targeted therapy